Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200675 | 0.87 | GABRA1 (0.55) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| Nitrogen SCHEMBL10979594 | 0.82 | GABRA1 (0.50) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL8082929 | 0.81 | TAAR1 (0.63) | PNMTTAAR1IDO1DRD2DRD3 | |
| SCHEMBL9289933 | 0.81 | CSNK2A2 (0.51) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL1046729 | 0.80 | PNMT (0.62) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL14718471 | 0.79 | TAAR1 (0.61) | PNMTTAAR1IDO1DRD2DRD3 | |
| SCHEMBL3302008 | 0.79 | PNMT (0.68) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL91282 | 0.79 | — | — | |
| SCHEMBL30633058 | 0.79 | — | — | |
| SCHEMBL3790392 | 0.78 | GABRA1 (0.46) | PNMTTAAR1IDO1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106237652-B | Method is selectively adsorbing and separating using molecular sieve as adsorbent | 上海复榆新材料科技有限公司 | 2019-09-20 | — | — | CN | claimed |
| CN-106237652-A | Molecular sieve is utilized to be selectively adsorbing and separating method as adsorbent | 上海复榆新材料科技有限公司 | 2016-12-21 | — | — | CN | claimed |
| CN-1075814-C | Process for preparing dihydroxyl silicate monomer and its polymers | HUANAN SCIENCE & ENGINEERING (CN) | 2001-12-05 | — | — | CN | claimed |
| CN-1238333-A | Process for preparing dihydroxyl silicate monomer and its polymers | HUANAN SCIENCE & ENGINEERING (CN) | 1999-12-15 | — | — | CN | claimed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023187182-A1 | PYRAZOLOPYRAZINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2023-10-05 | — | — | WO | disclosed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20220251117-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-4362864-A | Process for the preparation of polyarylene sulphides | BAYER AKTIENGESELLSCHAFT (DE) | 1982-12-07 | — | — | US | disclosed |
| US-4331801-A | Process for the preparation of polyarylene sulphides | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| US-4303781-A | Process for the preparation of polyarylene sulphides | BAYER AKTIENGESELLSCHAFT (DE) | 1981-12-01 | — | — | US | disclosed |
| US-4225567-A | GELATION INHIBITION | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1980-09-30 | — | — | US | disclosed |
| US-4180690-A | COBALT OXIDE, CHROMIUM OXIDE, ALUMINA, AND MAGNESIUM OXIDE CATALYST | UOP INC. (US) | 1979-12-25 | — | — | US | disclosed |
| US-4175058-A | COBALT OXIDE, CHROMIUM OXIDE, ALUMINA AND MAGNESIUM OXIDE WITH A SILICA CARRIER | UOP INC. (US) | 1979-11-20 | — | — | US | disclosed |
| US-4133837-A | Preferential aliphatic halogenation of ar-substituted alkylbenzenes | THE DOW CHEMICAL COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4087473-A | Preferential aliphatic halogenation of ar-substituted alkylbenzenes | THE DOW CHEMICAL COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | PNMT 4648/4885TAAR1 3829/4885IDO1 2278/4885 |
| US-20220251117-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PNMT 3471/4885TAAR1 4427/4885IDO1 3112/4885 |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | PNMT 2030/4885TAAR1 107/4885IDO1 861/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | PNMT 4806/4885TAAR1 4793/4885IDO1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.